{"organizations": [], "uuid": "5ea50f10c8e94c6fd8665b6281eedf6b9042196c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/indivior-results/britains-indivior-q1-profit-down-5-pct-idUSL3N1S91Z4", "country": "US", "domain_rank": 408, "title": "Britain's Indivior Q1 profit down 5 pct", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T09:28:00.000+03:00", "replies_count": 0, "uuid": "5ea50f10c8e94c6fd8665b6281eedf6b9042196c"}, "author": "", "url": "https://www.reuters.com/article/indivior-results/britains-indivior-q1-profit-down-5-pct-idUSL3N1S91Z4", "ord_in_thread": 0, "title": "Britain's Indivior Q1 profit down 5 pct", "locations": [], "entities": {"persons": [{"name": "sunil nair", "sentiment": "none"}, {"name": "indivior", "sentiment": "none"}, {"name": "justin george varghese", "sentiment": "none"}], "locations": [{"name": "britain", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 6:28 AM / Updated 12 minutes ago Britain's Indivior Q1 profit down 5 pct Reuters Staff 1 Min Read\nMay 2 (Reuters) - Britain’s Indivior posted a 5 percent fall in quarterly profit, bogged down by a drop in U.S. market share for its best-selling treatment, Suboxone Film, due to competition from generic versions.\nThe maker of drugs that treat opioid addiction posted a pretax profit of $111 million for the three months ended March 31, from $117 million a year ago.\nHowever, the company’s best-selling opioid addiction drug’s U.S. market share fell sharply to 55 percent year-to-date from 60 percent in the same period last year. Reporting By Justin George Varghese in Bengaluru; Editing by Sunil Nair", "external_links": [], "published": "2018-05-02T09:28:00.000+03:00", "crawled": "2018-05-02T09:45:48.018+03:00", "highlightTitle": ""}